This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00370214
Recruitment Status : Completed
First Posted : August 31, 2006
Last Update Posted : May 17, 2013
Sponsor:
Information provided by (Responsible Party):
Actelion

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients. All consecutive consenting patients diagnosed with WHO Group I PAH according to specific hemodynamic criteria at participating institutions will be enrolled. Participating patients will be followed for a minimum of five years from the time of enrollment.

Condition or disease
Pulmonary Hypertension

Detailed Description:

Pulmonary arterial hypertension (PAH) is a chronic, progressive, and often fatal disease characterized by severe constriction of the blood vessels in the lungs. Over the past decade, significant strides have been made in the medical management and understanding of PAH. However, much remains to be learned about the clinical course of both idiopathic PAH and associated PAH, including clinical presentation, pace of progression, key parameters to monitor, impact of treatment, and prognosticators of outcome. As the unique body of knowledge generated by the REVEAL Registry grows, it is hoped that new understandings, insights, and treatments will emerge that will improve the lives of patients with PAH.

The REVEAL Registry will provide investigators with descriptive data regarding the clinical course and treatment outcomes in patients with WHO Group I PAH. Data derived from the study may offer important tools for assessing current management practices of treating investigators, as well as changes over time. Additionally, the relationship of patient- and disease-specific parameters to patient outcomes may be able to be assessed through analysis of data from this study.

The specific objectives of the REVEAL Registry™ are to:

  • Characterize the demographics and clinical course of PAH patients
  • Evaluate and compare patient outcomes
  • Identify clinical predictors of short-term and long-term clinical outcomes
  • Assess the relationship between PAH medications and patient outcomes
  • Report temporal trends in treatments and outcomes for newly diagnosed patients
  • Collect timely and relevant data for the evolving research needs of the PAH community
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 3515 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
Study Start Date : March 2006
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Survival [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. clinical predictors, precise outcome definitions [ Time Frame: 5 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with WHO Group I Pulmonary Arterial Hypertension from US based PAH centers.
Criteria

Inclusion Criteria:

  • Newly diagnosed or previously diagnosed patients with WHO Group I PAH.
  • Documentation of the following hemodynamic parameters by right heart catheterization, performed at any time prior to study enrollment:
  • Mean pulmonary arterial pressure (mPAP) >25 mm Hg at rest or mPAP > 30 mm Hg with exercise contemporaneous with a pulmonary wedge pressure ≤ 18 mm Hg
  • Pulmonary wedge pressure ≤ 18 mm Hg
  • Pulmonary vascular resistance (PVR) ≥ 240 dynes.sec.cm-5 (i.e., ≥ 3.0 Wood units)

Exclusion Criteria:

  • Patients who meet the criteria for inclusion into WHO Groups II, III, IV or V
  • Have not had documentation of hemodynamic criteria for PAH by right heart catheterization at some time preceding study entry and following development of symptoms associated with PAH.
  • Do not meet the required hemodynamic criteria for entry into the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00370214


Locations
Show Show 54 study locations
Sponsors and Collaborators
Actelion
Investigators
Layout table for investigator information
Study Chair: Michael D. McGoon, M.D. Mayo Clinic - Rochester, Minnesota
Study Director: David B. Badesch, M.D. University of Colorado, Denver
Study Director: Robyn J. Barst, M.D. Columbia University
Study Director: Raymond Benza, M.D. University of Alabama at Birmingham
Study Director: Gregory Elliott, M.D. LDS Hospital
Study Director: Harrison Farber, M.D. Boston Medical Center
Study Director: Adaani Frost, M.D. Baylor College of Medicine
Study Director: Abby Krichman, RRT Duke University Pulmonary Vascular Disease Center
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Actelion
ClinicalTrials.gov Identifier: NCT00370214    
Other Study ID Numbers: CR001
First Posted: August 31, 2006    Key Record Dates
Last Update Posted: May 17, 2013
Last Verified: May 2013
Keywords provided by Actelion:
Pulmonary arterial hypertension
Lung diseases
Heart diseases
Pulmonary circulation
 Vascular resistance
PAH
Hypertension
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Hypertension
Vascular Diseases
 Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases